Bortezomib potentially inhibits cellular growth of vascular endothelial cells through suppression of G2/M transition

Bortezomib, a selective 26S proteasome inhibitor, has shown clinical benefits against refractory multiple myeloma. The indirect anti‐angiogenic activity of bortezomib has been widely recognized; however, the growth‐inhibitory mechanism of bortezomib on vascular endothelial cells remains unclear, esp...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Cancer science 2010-06, Vol.101 (6), p.1403-1408
Hauptverfasser:	Tamura, Daisuke, Arao, Tokuzo, Tanaka, Kaoru, Kaneda, Hiroyasu, Matsumoto, Kazuko, Kudo, Kanae, Aomatsu, Keiichi, Fujita, Yoshihiko, Watanabe, Takashi, Saijo, Nagahiro, Kotani, Yoshikazu, Nishimura, Yoshihiro, Nishio, Kazuto
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Apoptosis - drug effects Biological and medical sciences Boronic Acids - pharmacology Bortezomib Capillary Permeability - drug effects CDC2 Protein Kinase Cell Division - drug effects Cell Proliferation - drug effects Cells, Cultured Cyclin B - antagonists & inhibitors Cyclin-Dependent Kinases Endothelial Cells - drug effects Endothelial Cells - physiology G2 Phase - drug effects Humans Medical sciences Original Proteasome Endopeptidase Complex Proteasome Inhibitors Pyrazines - pharmacology Tumors Vascular Endothelial Growth Factor A - physiology
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!